查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1953457

腺結合病毒（AAV）載體生產市場－全球產業規模、佔有率、趨勢、機會及預測（按營運規模、方法、治療領域、應用、地區及競爭格局分類，2021-2031年）

Adeno Associated Virus Vector Manufacturing Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Scale of Operation, By Method, By Therapeutics Area, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球腺結合病毒（AAV）載體生產市場預計將從 2025 年的 14.8 億美元成長到 2031 年的 29.8 億美元，複合年成長率為 12.37%。

腺相關病毒（AAV）載體源自非致病性細小病毒，可作為人工病毒遞送系統，將治療性遺傳物質導入宿主細胞，用於治療遺傳性疾病。市場擴張的關鍵促進因素是慢性病盛行率的不斷上升以及基因療法監管核准的日益增多，而基因療法需要大規模的商業化生產能力。這些根本因素並非暫時的市場趨勢，而是對治療藥物供應和供應鏈可靠性的長期需求。

市場概覽
預測期 2027-2031
市場規模：2025年 14.8億美元
市場規模：2031年 29.8億美元
複合年成長率：2026-2031年 12.37%
成長最快的細分市場 臨床
最大的市場 北美洲

然而，該產業在生產擴充性面臨著巨大的挑戰，尤其是在實現高病毒滴度和有效去除純化過程中的空衣殼方面，技術難度較高。隨著臨床專案推進到商業化產品階段，這項生產瓶頸為供應鏈帶來了複雜的難題。據美國基因與細胞治療學會（ASGCT）稱，該領域已取得重大里程碑式進展，預計將有七種新型細胞和基因治療產品在2024年獲得FDA核准。這些治療方法的商業化進程不斷加快，給現有的生產基礎設施帶來了巨大壓力，使其難以維持穩定且經濟高效的供應。

市場促進因素

基於腺相關病毒（AAV）的基因治療臨床研發管線不斷擴展，需要可擴展的生產能力來支援後期臨床試驗和商業化部署，從而推動市場擴張。隨著候選療法從藥物發現進入法規核准階段，對高品質病毒載體的需求日益成長，迫切需要解決上游工程的產量限制問題。監管核准前景的樂觀也印證了這項發展勢頭。根據Oribiotech Ltd於2025年初發布的《再生醫學聯盟2025年第一季趨勢》報告，有六種治療方法被確定為2025年或2026年FDA加速核准途徑的候選療法。此外，一些擁有前景廣闊的載體資產的公司也正在獲得大規模投資。例如，AAVantgarde Bio公司在B輪資金籌措中籌集了1.41億美元，用於推進其AAV基因增強計畫（Vestbee，《2025年11月歐洲主要資金籌措輪次結束》，2025年12月版）。

同時，對合約研發生產機構（CDMO）日益成長的策略依賴正在改變供應鏈結構。生物製藥公司經常將生產外包給專業合作夥伴，以避免建立內部基礎設施相關的資本風險，並利用其在衣殼生產方面的技術專長。 2025年10月納斯達克一篇題為《牛津生物醫藥公司以450萬美元收購北卡羅來納州基因治療工廠》的報導重點介紹了這種產能整合趨勢。該公司收購了北卡羅來納州一家商業規模的病毒載體生產工廠，以增強其腺相關病毒（AAV）服務能力。這種依賴性使創新者能夠專注於進行臨床試驗，同時利用CDMO的專業工業規模資源。

市場挑戰

全球腺結合病毒（AAV）載體生產市場面臨的主要障礙是生產擴充性不足，這主要是由於難以獲得高病毒滴度和有效去除空衣殼等技術難題造成的。隨著研發人員將候選療法從臨床試驗過渡到商業化生產，現有生產平台往往無法在不增加過多成本的情況下維持所需的產量和純度標準。這種技術效率低下造成了嚴重的生產瓶頸，導致供不應求和銷貨成本上升，最終限制了可整合到醫療保健系統中的治療方法數量。

無法有效擴大生產規模正在阻礙市場成長，導致製造商無法滿足日益成長的載體需求。有限的生產能力與不斷擴大的開發平臺之間的差距日益凸顯。根據美國基因與細胞治療學會2024年第三季報告，全球基因、細胞和RNA療法的研發管線已擴展至4,000多個候選藥物。目前的基礎設施不足以支持如此龐大的潛在商業產品數量，從而抑制了AAV載體生產行業的盈利能力和整體成長勢頭。

市場趨勢

從貼壁培養系統轉向懸浮培養系統的轉變，正從根本上改變AAV的生產方式，顯著提升商業性產量。製造商正迅速以懸浮培養平台取代勞力密集的貼壁培養技術，從而實現生物反應器內的規模化生產。 Forge Biologics公司在2024年10月發布的「FUEL AAV生產平台」新聞稿中詳細介紹了這一轉變，該平台推出了一種新型懸浮培養生產平台，其生產效率比行業標準提高了2-6倍。這些創新使研發人員能夠克服傳統方法的產能限制，並高效生產高效價病毒載體，以滿足後期臨床試驗日益成長的需求。

同時，人工智慧驅動的衣殼設計與製程最佳化相結合，正在革新載體工程，以應對組織標靶化和免疫抗原性的挑戰。開發人員正在利用機器學習演算法分析龐大的衣殼變體庫，並設計具有增強遞送特性的合成載體。這一趨勢吸引了大量資本投資。根據Dyno Therapeutics於2024年10月發布的新聞稿《Dyno Therapeutics與羅氏建立新的戰略聯盟》，該公司簽署了一項協議，利用其人工智慧驅動的平台進行下一代載體設計。該協議包括5000萬美元的首付款，以及超過10億美元的潛在里程碑付款。借助這些計算工具，市場正在從天然血清型向最佳化載體發展，從而提高治療效果和生產效率。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

5. 全球腺結合病毒（AAV）載體生產市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依營運規模（臨床、臨床前、商業化）
    • 依方法（體外、體內）
    • 依治療領域（血液疾病、感染疾病、遺傳性疾病、神經系統疾病、眼科疾病、其他）
    • 依應用領域（細胞療法、基因療法、疫苗）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美腺結合病毒（AAV）載體生產市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲腺結合病毒（AAV）載體生產市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區腺結合病毒（AAV）載體生產市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲腺結合病毒（AAV）載體生產市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美腺結合病毒（AAV）載體生產市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

13. 全球腺結合病毒（AAV）載體生產市場：SWOT分析

第14章 波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Catalent
  • Lonza
  • Thermo Fisher Scientific
  • WuXi AppTec
  • Charles River Laboratories
  • AGC Biologics
  • Novasep
  • Vectalys
  • uniQure

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 26748

The Global Adeno-Associated Virus (AAV) Vector Manufacturing Market is projected to expand from USD 1.48 Billion in 2025 to USD 2.98 Billion by 2031, registering a CAGR of 12.37%. AAV vectors act as engineered viral delivery systems derived from non-pathogenic parvoviruses, designed to transport therapeutic genetic material into host cells to treat genetic disorders. Market expansion is primarily propelled by the growing prevalence of chronic diseases and a rise in regulatory approvals for gene therapies, which necessitate substantial commercial production capabilities. These foundational drivers are distinct from temporary market trends, creating a long-term requirement for therapeutic availability and supply chain reliability.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.48 Billion
Market Size 2031USD 2.98 Billion
CAGR 2026-203112.37%
Fastest Growing SegmentClinical
Largest MarketNorth America

However, the industry faces significant hurdles regarding manufacturing scalability, specifically due to the technical complexities involved in reaching high viral titers and effectively removing empty capsids during purification. This production bottleneck creates complications within the supply chain as clinical programs evolve into commercial products. According to the American Society of Gene & Cell Therapy, the sector reached a major milestone in 2024 with the FDA approval of seven new cell and gene therapy products. This increase in commercialized therapies exerts considerable strain on current manufacturing infrastructure to maintain a consistent and cost-efficient supply.

Market Driver

The growth of the AAV-based gene therapy clinical pipeline stimulates market expansion by demanding scalable production capacities to sustain late-stage trials and commercial rollouts. As therapeutic candidates advance from the discovery phase to regulatory review, the requirement for high-quality viral vectors increases, intensifying the need to resolve upstream yield constraints. This momentum is highlighted by the strong array of expected regulatory outcomes; according to Oribiotech Ltd, citing the 'Alliance for Regenerative Medicine's Q1 2025 trends' report published in early 2025, six therapies were identified as candidates for the FDA's Accelerated Approval pathway in 2025 or 2026. Additionally, substantial investment is targeting companies with promising vector assets, as demonstrated when AAVantgarde Bio raised $141 million in Series B funding to progress its AAV gene-augmentation programs, according to Vestbee's 'Top European funding rounds closed in November 2025' report from December 2025.

Simultaneously, the increasing strategic dependence on Contract Development and Manufacturing Organizations (CDMOs) is transforming the supply chain structure. Biopharmaceutical firms are frequently outsourcing to specialized partners to avoid the capital risks associated with constructing internal infrastructure and to utilize technical expertise in capsid production. This shift toward capacity consolidation was emphasized when, according to a Nasdaq article from October 2025 titled 'Oxford Biomedica Acquires $4.5 Mln North Carolina Gene Therapy Facility,' Oxford Biomedica purchased a commercial-scale viral vector manufacturing site in North Carolina to specifically bolster its AAV service offerings. This reliance enables innovators to concentrate on clinical execution while capitalizing on the dedicated industrial-scale resources of CDMOs.

Market Challenge

The principal obstacle hindering the Global Adeno-Associated Virus (AAV) Vector Manufacturing Market is the deficiency in manufacturing scalability, stemming from the technical difficulties in attaining high viral titers and effectively eliminating empty capsids. As developers move therapeutic candidates from clinical trials to commercial-scale operations, existing production platforms often fail to sustain required yield and purity standards without incurring excessive costs. This technical inefficiency generates a significant production bottleneck, leading to supply shortages and increased costs of goods sold, which ultimately limits the number of therapies that can be successfully commercialized and integrated into healthcare systems.

This failure to scale production efficiently impedes market growth, preventing manufacturers from meeting the rising demand for vector supplies. The gap between restricted manufacturing capacity and the widening development pipeline is becoming increasingly distinct. According to the American Society of Gene & Cell Therapy's Q3 2024 report, the global pipeline for gene, cell, and RNA therapies has grown to encompass over 4,000 candidates in development. Current infrastructure is insufficient to support this massive volume of potential commercial products, thereby suppressing the revenue potential and overall growth trajectory of the AAV vector manufacturing sector.

Market Trends

The shift from adherent to suspension cell culture systems is fundamentally transforming AAV production by facilitating higher commercial yields. Manufacturers are swiftly replacing labor-intensive adherent techniques with suspension-based platforms that enable scalability within bioreactors. This transition was illustrated when Forge Biologics launched a new suspension-based manufacturing platform in October 2024, as detailed in their 'Forge Biologics Announces the FUEL AAV Manufacturing Platform' press release, which is capable of delivering a 2-6x increase in productivity over industry norms. Such innovations enable developers to surpass the volume constraints of traditional methods, ensuring that high-titer viral vectors can be produced efficiently to satisfy the rising requirements of late-stage clinical trials.

Concurrently, the integration of Artificial Intelligence for capsid design and process optimization is revolutionizing vector engineering to tackle challenges related to tissue targeting and immunogenicity. Developers are utilizing machine learning algorithms to analyze extensive libraries of capsid variants, engineering synthetic vectors with enhanced transduction profiles. This trend drew substantial capital investment when, according to a Dyno Therapeutics press release from October 2024 titled 'Dyno Therapeutics Forms New Strategic Partnership With Roche,' the company finalized a deal involving a $50 million upfront payment and potential milestones surpassing $1 billion to utilize its AI-driven platform for designing next-generation vectors. By employing these computational tools, the market is advancing beyond naturally occurring serotypes toward optimized vehicles that improve therapeutic efficacy and manufacturability.

Key Market Players

  • Catalent
  • Lonza
  • Thermo Fisher Scientific
  • WuXi AppTec
  • Charles River Laboratories
  • AGC Biologics
  • Novasep
  • Vectalys
  • uniQure

Report Scope

In this report, the Global Adeno-Associated Virus (AAV) Vector Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Adeno-Associated Virus (AAV) Vector Manufacturing Market, By Scale of Operation

  • Clinical
  • Preclinical
  • Commercial

Adeno-Associated Virus (AAV) Vector Manufacturing Market, By Method

  • In Vitro
  • In Vivo

Adeno-Associated Virus (AAV) Vector Manufacturing Market, By Therapeutics Area

  • Hematological Diseases
  • Infectious Diseases
  • Genetic Disorders
  • Neurological Disorders
  • Ophthalmic Disorders
  • Others

Adeno-Associated Virus (AAV) Vector Manufacturing Market, By Application

  • Cell Therapy
  • Gene Therapy
  • Vaccine

Adeno-Associated Virus (AAV) Vector Manufacturing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Adeno-Associated Virus (AAV) Vector Manufacturing Market.

Available Customizations:

Global Adeno-Associated Virus (AAV) Vector Manufacturing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Scale of Operation (Clinical, Preclinical, Commercial)
    • 5.2.2. By Method (In Vitro, In Vivo)
    • 5.2.3. By Therapeutics Area (Hematological Diseases, Infectious Diseases, Genetic Disorders, Neurological Disorders, Ophthalmic Disorders, Others)
    • 5.2.4. By Application (Cell Therapy, Gene Therapy, Vaccine)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Scale of Operation
    • 6.2.2. By Method
    • 6.2.3. By Therapeutics Area
    • 6.2.4. By Application
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Scale of Operation
        • 6.3.1.2.2. By Method
        • 6.3.1.2.3. By Therapeutics Area
        • 6.3.1.2.4. By Application
    • 6.3.2. Canada Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Scale of Operation
        • 6.3.2.2.2. By Method
        • 6.3.2.2.3. By Therapeutics Area
        • 6.3.2.2.4. By Application
    • 6.3.3. Mexico Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Scale of Operation
        • 6.3.3.2.2. By Method
        • 6.3.3.2.3. By Therapeutics Area
        • 6.3.3.2.4. By Application

7. Europe Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Scale of Operation
    • 7.2.2. By Method
    • 7.2.3. By Therapeutics Area
    • 7.2.4. By Application
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Scale of Operation
        • 7.3.1.2.2. By Method
        • 7.3.1.2.3. By Therapeutics Area
        • 7.3.1.2.4. By Application
    • 7.3.2. France Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Scale of Operation
        • 7.3.2.2.2. By Method
        • 7.3.2.2.3. By Therapeutics Area
        • 7.3.2.2.4. By Application
    • 7.3.3. United Kingdom Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Scale of Operation
        • 7.3.3.2.2. By Method
        • 7.3.3.2.3. By Therapeutics Area
        • 7.3.3.2.4. By Application
    • 7.3.4. Italy Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Scale of Operation
        • 7.3.4.2.2. By Method
        • 7.3.4.2.3. By Therapeutics Area
        • 7.3.4.2.4. By Application
    • 7.3.5. Spain Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Scale of Operation
        • 7.3.5.2.2. By Method
        • 7.3.5.2.3. By Therapeutics Area
        • 7.3.5.2.4. By Application

8. Asia Pacific Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Scale of Operation
    • 8.2.2. By Method
    • 8.2.3. By Therapeutics Area
    • 8.2.4. By Application
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Scale of Operation
        • 8.3.1.2.2. By Method
        • 8.3.1.2.3. By Therapeutics Area
        • 8.3.1.2.4. By Application
    • 8.3.2. India Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Scale of Operation
        • 8.3.2.2.2. By Method
        • 8.3.2.2.3. By Therapeutics Area
        • 8.3.2.2.4. By Application
    • 8.3.3. Japan Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Scale of Operation
        • 8.3.3.2.2. By Method
        • 8.3.3.2.3. By Therapeutics Area
        • 8.3.3.2.4. By Application
    • 8.3.4. South Korea Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Scale of Operation
        • 8.3.4.2.2. By Method
        • 8.3.4.2.3. By Therapeutics Area
        • 8.3.4.2.4. By Application
    • 8.3.5. Australia Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Scale of Operation
        • 8.3.5.2.2. By Method
        • 8.3.5.2.3. By Therapeutics Area
        • 8.3.5.2.4. By Application

9. Middle East & Africa Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Scale of Operation
    • 9.2.2. By Method
    • 9.2.3. By Therapeutics Area
    • 9.2.4. By Application
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Scale of Operation
        • 9.3.1.2.2. By Method
        • 9.3.1.2.3. By Therapeutics Area
        • 9.3.1.2.4. By Application
    • 9.3.2. UAE Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Scale of Operation
        • 9.3.2.2.2. By Method
        • 9.3.2.2.3. By Therapeutics Area
        • 9.3.2.2.4. By Application
    • 9.3.3. South Africa Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Scale of Operation
        • 9.3.3.2.2. By Method
        • 9.3.3.2.3. By Therapeutics Area
        • 9.3.3.2.4. By Application

10. South America Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Scale of Operation
    • 10.2.2. By Method
    • 10.2.3. By Therapeutics Area
    • 10.2.4. By Application
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Scale of Operation
        • 10.3.1.2.2. By Method
        • 10.3.1.2.3. By Therapeutics Area
        • 10.3.1.2.4. By Application
    • 10.3.2. Colombia Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Scale of Operation
        • 10.3.2.2.2. By Method
        • 10.3.2.2.3. By Therapeutics Area
        • 10.3.2.2.4. By Application
    • 10.3.3. Argentina Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Scale of Operation
        • 10.3.3.2.2. By Method
        • 10.3.3.2.3. By Therapeutics Area
        • 10.3.3.2.4. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Adeno-Associated Virus (AAV) Vector Manufacturing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Catalent
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Lonza
  • 15.3. Thermo Fisher Scientific
  • 15.4. WuXi AppTec
  • 15.5. Charles River Laboratories
  • 15.6. AGC Biologics
  • 15.7. Novasep
  • 15.8. Vectalys
  • 15.9. uniQure

16. Strategic Recommendations

17. About Us & Disclaimer